Drug interactions
Larotrectinib + Umeclidinium-vilanterol
Severity: Minor
Larotrectinib and Umeclidinium-vilanterol: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Larotrectinib is a modest CYP3A4 inhibitor and could marginally raise vilanterol exposure. Clinical impact is expected to be small.
What this interaction means in plain words
Larotrectinib and Umeclidinium-vilanterol have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Larotrectinib belongs to Oncology; Umeclidinium-vilanterol belongs to Respiratory.
Why it happens
Larotrectinib weakly inhibits CYP3A4, slightly reducing vilanterol clearance.
What to do
No routine adjustment is required; monitor for beta-agonist adverse effects such as tachycardia.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Larotrectinib and Umeclidinium-vilanterol, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Umeclidinium-vilanterol
Other interactions of Larotrectinib
Frequently asked questions
Can I take Larotrectinib with Umeclidinium-vilanterol?
MediHelp rates the interaction as minor. Larotrectinib and Umeclidinium-vilanterol have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Larotrectinib is a modest CYP3A4 inhibitor and could marginally raise vilanterol exposure. Clinical impact is expected to be small.
How serious is the interaction between Larotrectinib and Umeclidinium-vilanterol?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No routine adjustment is required; monitor for beta-agonist adverse effects such as tachycardia.
What other medicines interact with Umeclidinium-vilanterol?
MediHelp also lists interactions of Umeclidinium-vilanterol with, for example, Aclidinium, Amiodarone, Amitriptyline. The full list is on the Umeclidinium-vilanterol page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
